GPT and metabolic dysfunction-associated steatotic liver disease: These outcome data are analysed with the random-effects model, and compared to control group for type 2 diabetes complicated with non-alcoholic fatty liver disease, dapagliflozin treatment is associated with significantly reduced ALT (SMD=-1.27; 95% CI=-1.60 to -0.95; P<0.00001) with no heterogeneity among the studies (I2=0%, heterogeneity P=0.65, Figure 2A), and AST (SMD=-1.37; 95% CI=-2.08 to -0.65; P=0.0002) with significant heterogeneity among the studies (I2=71%, heterogeneity P=0.06, Figure 2B).